UPCNasdaqPharmaceutical PreparationsFiscal year ends September 30
Universe Pharmaceuticals INC
Financials through fiscal 2025, year ended Sep 30, 2025Last filing: 20-F on Jan 29, 2026
$3.76−0.17 (-4.33%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$1.47 (−28.11%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
Universe Pharmaceuticals INC saw revenue fall 22.4% to $17.86B over fiscal 2025. Free cash flow was -$5.32B.
Revenue
$17.86B
-22.4% vs. a year earlier
Operating income
-$2.92B
FY2025
Free cash flow
-$5.32B
FY2025
EPS, diluted
-$8.06
FY2025
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Mar 31, 2026
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $17.86B
- Net income
- -$3.67B
- EPS, diluted
- -$8.06
- Free cash flow
- -$5.32B
Eight years at a glance
Fiscal years 2018 to 2025, USD
Revenue
$17.86B-22.4% YoY
Gross profit
$6.30B+3.8% YoY
Operating income
-$2.92B
Net income
-$3.67B
EPS, diluted
-$8.06
Free cash flow
-$5.32B
Reported period